StockVS

Lumexa Imaging Holdings, Inc. (LMRI) स्टॉक विश्लेषण

स्वास्थ्य सेवा

Lumexa Imaging Holdings, Inc.

$8.17

+$0.17 (+2.12%)

अंतिम अपडेट: 26 मई 2026

प्राइस हिस्ट्री

विश्लेषण

कंपनी का अवलोकन

Lumexa Imaging Holdings, Inc. (LMRI) operates within the healthcare sector, specifically focusing on the medical devices industry, where it owns and operates diagnostic imaging centers across the United States. The organization provides essential outpatient medical imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), X-ray, and ultrasound procedures to patients. The company maintains a significant scale with a total market capitalization of $893.82M and an annual revenue of $1.02B, supported by a workforce of 4064 employees. These financial figures indicate that Lumexa Imaging Holdings, Inc. is a substantial entity within its niche, generating over a billion dollars in revenue while employing a large team to deliver specialized diagnostic capabilities.

वित्तीय स्वास्थ्य

The company reported a trailing twelve-month revenue of $1.02B, yet it recorded a net income of -$47,104,000, revealing a substantial gap between top-line sales and bottom-line profitability. Despite this net loss, the enterprise generated positive EBITDA of $91.96M, which suggests that operating expenses are a primary driver of the reported net loss rather than core operational inefficiencies. The firm maintains a gross margin of 15.4%, indicating that after direct costs of goods sold, the company retains a moderate portion of revenue. Operating margins stand at 1.7%, reflecting high overhead costs typical of service-oriented medical imaging businesses, while profit margins are negative at -4.6%, confirming the current unprofitability on a net basis. Liquidity is supported by $58.83M in cash, though this is offset by significant debt obligations totaling $962.50M. The balance sheet is highly leveraged, evidenced by a debt-to-equity ratio of 164.22, which highlights a capital structure reliant on substantial debt financing. Short-term liquidity appears manageable with a current ratio of 1.27, suggesting the company has sufficient current assets to cover its current liabilities. Return on Equity is negative at -12.6%, indicating that shareholders are currently seeing a dilution of value, while Return on Assets sits at 1.9%, showing minimal asset efficiency given the high debt load.

मूल्यांकन आकलन

The valuation metrics present a complex picture, with the trailing P/E ratio listed as N/A due to the lack of recent earnings, while the forward P/E is calculated at 9.23. This discrepancy implies that the market anticipates future earnings growth sufficient to justify a multiple, although the negative historical earnings prevent a trailing valuation assessment. The price-to-book ratio stands at 1.53, suggesting that the market values the company at a premium of 53% over its net asset book value. Alternative valuation metrics, such as the price-to-sales ratio of 0.87 and an EV/EBITDA of 19.55, provide context by linking value directly to revenue and earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week low of $7.23 and a high of $19.45, with the current price sitting at a specific point within this volatility range relative to these historical bounds. The beta value is listed as N/A, meaning that the specific volatility relative to the broader market index cannot be quantified with the available data points.

Growth & Income

Revenue growth year-over-year is reported at 7.9%, demonstrating a steady expansion in the top line, whereas earnings growth is N/A due to the company's negative net income position. Since earnings are negative, they cannot grow faster than revenue in the traditional sense, and the focus remains on expanding the revenue base to eventually drive profitability. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash flow is reinvested into operations or used to service debt rather than distributed to shareholders. This reinvestment strategy is typical for growth-stage companies that prioritize capital allocation toward business expansion over immediate shareholder returns. The overall growth and income profile reflects a capital-intensive business model currently prioritizing market share and service volume recovery over income generation.

समकक्ष तुलना

Lumexa Imaging Holdings, Inc. (LMRI) चिकित्सा उपकरण उद्योग में कार्यरत है। बाजार पूंजीकरण के आधार पर इसके निकटतम समकक्षों से तुलना इस प्रकार है:

कंपनी टिकर मार्केट कैप P/E अनुपात
Lumexa Imaging Holdings, Inc. LMRI $784.98M N/A
Abbott Laboratories ABT $150.96B 24.3
Stryker Corporation SYK $119.99B 36.2
Medtronic plc MDT $99.63B 21.7

चिकित्सा उपकरण उद्योग का औसत P/E अनुपात 60.2x है। Lumexa Imaging Holdings, Inc. का P/E अनुपात N/A है।

यह विश्लेषण AI द्वारा केवल सूचनात्मक उद्देश्यों के लिए तैयार किया गया है और यह वित्तीय सलाह नहीं है। डेटा में देरी या अशुद्धि हो सकती है। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और किसी योग्य वित्तीय सलाहकार से परामर्श लें।

Lumexa Imaging Holdings, Inc. के बारे में

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. Lumexa Imaging Holdings, Inc. was founded in 2018 and is based in Raleigh, North Carolina.

कंपनी विवरण अंग्रेजी में दिखाया गया है।

वेबसाइट देखें →

मुख्य आंकड़े

मार्केट कैप
$784.98M
P/E अनुपात
N/A
52 सप्ताह उच्च
$19.45
52 सप्ताह निम्न
$6.45
औसत वॉल्यूम
1.08M

डेटा yfinance के माध्यम से Yahoo Finance द्वारा प्रदान किया गया है। दैनिक अपडेट।

कंपनी जानकारी

एक्सचेंज
NASDAQ
देश
United States
कर्मचारी
4,064